This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2000 Aug;6(8):2965-6.

Clinical use of tyrosine kinase inhibitors: therapy for chronic myelogenous leukemia and other cancers

N J Donato, M Talpaz

PMID: 10955770

Editorial

Clinical use of tyrosine kinase inhibitors: therapy for chronic myelogenous leukemia and other cancers

N J Donato et al. Clin Cancer Res. 2000 Aug.

. 2000 Aug;6(8):2965-6.

Authors

N J Donato, M Talpaz

PMID: 10955770

No abstract available

PubMed Disclaimer

Comment on

The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth.
Krystal GW, Honsawek S, Litz J, Buchdunger E. Krystal GW, et al. Clin Cancer Res. 2000 Aug;6(8):3319-26. Clin Cancer Res. 2000. PMID: 10955819

Similar articles

Tyrosine kinase inhibitors in chronic myeloid leukemia.
Sawyers CL, Druker B. Sawyers CL, et al. Cancer J Sci Am. 1999 Mar-Apr;5(2):63-9. Cancer J Sci Am. 1999. PMID: 10198725 Review. No abstract available.
[Tyrosine kinase inhibitors as the targeted therapy for leukemia].
Heikinheimo M. Heikinheimo M. Duodecim. 2000;116(18):1943-4. Duodecim. 2000. PMID: 12017607 Finnish. No abstract available.
[Molecular cancer therapy using tyrosine kinase inhibitors].
Lacotte-Thierry L, Guilhot F. Lacotte-Thierry L, et al. Rev Prat. 2002 Jan 15;52(2):121-3. Rev Prat. 2002. PMID: 11915553 French. No abstract available.
Current treatment approaches for chronic myelogenous leukemia.
Druker BJ. Druker BJ. Cancer J. 2001 Jul-Aug;7 Suppl 1:S14-8. Cancer J. 2001. PMID: 11504279 Review.
Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML.
Druker BJ. Druker BJ. Oncogene. 2002 Dec 9;21(56):8541-6. doi: 10.1038/sj.onc.1206081. Oncogene. 2002. PMID: 12476300 Review. No abstract available.

See all similar articles

Cited by

PTPROt inactivates the oncogenic fusion protein BCR/ABL and suppresses transformation of K562 cells.
Motiwala T, Majumder S, Ghoshal K, Kutay H, Datta J, Roy S, Lucas DM, Jacob ST. Motiwala T, et al. J Biol Chem. 2009 Jan 2;284(1):455-464. doi: 10.1074/jbc.M802840200. Epub 2008 Nov 7. J Biol Chem. 2009. Retraction in: J Biol Chem. 2018 Mar 9;293(10):3589. doi: 10.1074/jbc.W118.002431. PMID: 18997174 Free PMC article. Retracted.
Feature-similarity protein classifier as a ligand engineering tool.
Maddipati S, Fernández A. Maddipati S, et al. Biomol Eng. 2006 Dec;23(6):307-15. doi: 10.1016/j.bioeng.2006.09.004. Epub 2006 Oct 10. Biomol Eng. 2006. PMID: 17110166 Free PMC article.
An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.
Fernández A, Sanguino A, Peng Z, Ozturk E, Chen J, Crespo A, Wulf S, Shavrin A, Qin C, Ma J, Trent J, Lin Y, Han HD, Mangala LS, Bankson JA, Gelovani J, Samarel A, Bornmann W, Sood AK, Lopez-Berestein G. Fernández A, et al. J Clin Invest. 2007 Dec;117(12):4044-54. doi: 10.1172/JCI32373. J Clin Invest. 2007. PMID: 18060038 Free PMC article.
Mechanisms of transformation by the BCR/ABL oncogene.
Sattler M, Griffin JD. Sattler M, et al. Int J Hematol. 2001 Apr;73(3):278-91. doi: 10.1007/BF02981952. Int J Hematol. 2001. PMID: 11345193 Review.
Kinase packing defects as drug targets.
Crespo A, Fernández A. Crespo A, et al. Drug Discov Today. 2007 Nov;12(21-22):917-23. doi: 10.1016/j.drudis.2007.09.009. Epub 2007 Oct 30. Drug Discov Today. 2007. PMID: 17993409 Free PMC article. Review.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information